BrainsWay
BrainsWay was established in 2003 and is based in Jerusalem, Israel. The Deep Transcranial Magnetic Stimulation (Deep TMS) system is the company's main product, and it uses a unique proprietary coil design to activate deeper and larger brain regions than other TMS technologies.
Deep TMS has received regulatory clearance in the United States, Europe, Canada, and Israel for the treatment of depression and OCD, and is currently undergoing clinical trials for other indications such as addiction, PTSD, and Alzheimer's disease. BrainsWay offers training and support to healthcare professionals who use its technology to treat patients in addition to medical devices.
In addition to being selected as a finalist in the 2020 Medical Design Excellence Awards and earning the Innovation of the Year Award at the 2019 Israeli Business Excellence Awards, the company has won acclaim for its revolutionary technologies. BrainsWay is dedicated to furthering neuromodulation research and improving the lives of patients suffering from neurological and psychological diseases.
BrainsWay has reported approximately $31.5 million in sales for fiscal year 2023 and anticipates future growth. BrainsWay specializes in identifying safe and effective remedies for neurological and mental problems through ongoing research and collaboration with recognized medical specialists.
Founded: 2003
Headquarters: 19 Hartum St Bynet Building Har Hotzvim, Jerusalem, Jerusalem, Isreal
Website: https://www.brainsway.com/
